Back to Health

Who Should Avoid Abacavir?

Who Should Avoid Abacavir?
Bareback Guide 3 March 2026

The restrictions on abacavir are unusually clear-cut. One is absolute and genetically determined, and the others are the ordinary considerations that apply to choosing any regimen.

Who absolutely cannot take it?

Anyone carrying the HLA-B*5701 gene variant. This is determined by a blood test before the first dose and it is not a matter of degree. Carriers are not prescribed abacavir under any circumstances.

What about a previous reaction?

Anyone who has stopped abacavir because of suspected hypersensitivity must never take it again, permanently and without exception. Rechallenge can cause a rapid and potentially fatal reaction. This should be recorded prominently and carried with you.

What about liver impairment?

Abacavir is cleared by the liver. A reduced dose is used in mild hepatic impairment and it is not recommended in moderate or severe impairment. Since combination tablets cannot be adjusted, this usually means a different product.

What about cardiovascular risk?

Not a prohibition and a genuine consideration. Where someone has substantial existing risk, including previous heart disease, diabetes or several risk factors together, many clinicians prefer an alternative. It is a reasonable thing to raise if it applies to you.

What about hepatitis B?

Abacavir has no activity against hepatitis B. Anyone with chronic hepatitis B needs a regimen containing tenofovir or lamivudine to cover it, and switching to an abacavir-based combination without that cover risks a liver flare.

What about kidney impairment?

Not a barrier, and in fact one of abacavir's advantages. Because it is cleared by the liver rather than the kidneys, it can be used where tenofovir-containing regimens would be unsuitable.

What about a very high viral load?

Historically a concern with abacavir and lamivudine as the only backbone. Combining it with a potent third agent such as dolutegravir has largely resolved that, and this is factored in when a regimen is chosen.

What about pregnancy?

Abacavir is used in pregnancy with an established record. As always, anyone pregnant or planning a pregnancy should discuss it with their clinic rather than stopping anything, since untreated HIV carries far greater risk.

What about resistance?

Certain accumulated nucleoside mutations reduce abacavir's activity, and resistance testing determines whether it remains useful. That is a specialist assessment based on your full profile.

What are the alternatives?

Tenofovir disoproxil or tenofovir alafenamide, both with emtricitabine, which also cover hepatitis B. Two-drug regimens such as dolutegravir with lamivudine, which avoid both abacavir and tenofovir. Which suits you depends on kidney function, hepatitis status and resistance history.

Can you switch away easily?

Yes. Switching between nucleoside backbones is routine and viral suppression is maintained provided the rest of the regimen remains active. A decision now is not permanent.

Who decides?

You do, with a clinician, except on the genetic test, which is not negotiable. Beyond that, preferences about tablet size, dosing schedule and how a regimen fits your life are legitimate reasons rather than trivial ones.

What should you tell your clinic?

Your genetic test result if you know it, any previous reaction, your cardiovascular risk factors, your hepatitis B status and everything you take. An accurate picture produces a better prescription, and nothing you say is reported anywhere.

What if it is the only option available?

Rarely the case, and where it is, the genetic test still governs absolutely. HIV medicine now has enough options that almost every situation has an alternative, and being told otherwise is worth a second opinion.

Is a second opinion reasonable?

Entirely. If you have been told abacavir is your only option, or that you cannot change, asking to discuss it again or to see someone else is a normal part of care rather than a complaint about anyone.

What happens if you have to change?

Switching is routine and suppression is maintained provided the new regimen is fully active. Coming off abacavir is not a setback and it does not narrow your options later, since most changes are reversible.